Topiramate-induced psychotic exacerbation: Case report and review of literature

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue 4, 2007, Pages 285-290

  Karslioǧlu, Ersin Hatice ^a,d   Karakiliç, Hande ^b   Taner, Ender ^c   Coşar, Behçet ^c  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Turkish National Police   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d Anestezi ve Reanimasyon Klinigi   (Turkey)

Author keywords

Induced psychosis; Psychiatric adverse effects; Schizophrenia; Topiramate (TPM)

Indexed keywords

DANTROLENE; TOPIRAMATE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; ELECTROENCEPHALOGRAM; GRANDIOSE DELUSION; HEREDITARY MOTOR SENSORY NEUROPATHY; HOSPITAL ADMISSION; HUMAN; MALE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOSIS; SUICIDAL IDEATION; VISUAL HALLUCINATION;

EID: 36248933228     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500601117215     Document Type: Article

References (41)

1. Sabers AS, Gram L. Drug treatment of epilepsy in the 1990s: achievements and new developments. Drugs 1996;52:483-93.
2. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:1164-73.
3. Shank RP, Gardocki JF, Streater AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl 1):S3-9.
4. Marcotte D. Use of topiramate, a new anti-epileptic, as a mood stabilizer. J Affect Disord 1998;50:245-51.
5. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmocol 2002;449:121-5.
6. Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: A pharmacologic strategy for adressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003;26(4):199-206.
7. Chengappa KNR, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001;3:215-22.
8. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorder. Biol Psychiatry 2000;47:1025-33.
9. Andrade C. Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder. Bipolar Disord 2001;3(4):211-2.
10. Bertant JL. Topiramate in PTSD: Preliminary clinical observations. J Clin Psychiatry 2001;62(Suppl 17):60-3.
11. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: A clinical case series. J Clin Psychiatry 2000;61:368-72.
12. Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine and cluster headache with topiramate. Headache 2002;42:796-803.
13. Schuler-Springorum M, Hebebrand J, Wehmeier PM, Remschmidt H. Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 case reports. Z Kinder Jugendpsychiatr Psychother 2002;30(1):51-8.
14. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss [letter]. Can J Psychiatry 2000;45:198.
15. Khan A, Faught E, Gillian F, Kuzniecki R. Acute psychotic symptoms induced by topiramate. Seizure 1999;84:235-7.
16. Stella F, Caetano D, Cendes F, Guerreiro CA. Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 2002;60(2-A):285-7.
17. Verhoeven WM, Boermans JA, van der Heijden FM, Tuinier S. Psychosis following treatment with topiramate. Ned Tijdschr Geneeskd 2002;146(44):2093-5.
18. Matthews SC, Miller PB. Auditory hallucinations associated with topiramate. J Clin Psychiatry 2001;62(8):653.
19. Garcia Cabeza GI, Gutierrez Rodriguez M, Epifanio Gutierrez MM. Psychosis with topiramate. Actas Esp Psiquiatr 2000;28(3):202-4.
20. Biton V, Montouris GD, et al. A randomized placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.
21. Tassinari CA, Michelucci R, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
22. Hermann BP, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification consequences, and treatment of major depression. Epilepsia 2000;41:S31-41.
23. Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav 2000;1:37-51.
24. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155:325-36.
25. Trimble MR. The psychosis of epilepsy and their treatment. Clinical Neuropharmacology 1985;8:211-20.
26. Landolt H. Some clinical and electroencephalographical correlations in epileptic psychosis (twilight studies). Electroencephalogr Clin Neurophysiol 1953;5:121.
27. Wolf P. Acute behevioral symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or forced normalisation. In: Advances in neurology, vol. 55. New York: Raven Press; 1991. p 127-42.
28. Wiegartz P, Seidenberg M, Woodard A, et al. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology 1999;53(Suppl 2):S3-8.
29. Trimble MR, Rusch N, Betts T, Crawford PM. Psychiatric symptoms after therapy with new antiepileptic drugs: Psychopathological and seizure related variables. Seizure 2000;9:249-54.
30. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
31. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(Suppl 1):66-71.
32. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improve deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24:290-4.
33. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenic patient [letter]. J Clin Psychiatry 2003;64(10):1267-8.
34. Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment resistant schizophrenia: a naturalistic case series outcome study. J Psychopharmacol 2001;15:297-301.
35. Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991;121(1-2):77-80.
36. Kober D, Gabbard GO. Topiramate-induced psychosis. Am J Psychiatry 2005;162:1542.
37. Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia [letter]. Am J Psychiatry 2002;159:675.
38. Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003;4:548-52.
39. Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003;4(4):430-4.
40. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy Epilepsia 2003;44(5):659-63.
41. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 2001;24:43-9.